Immunocore Holdings plc (IMCR)
| Market Cap | 1.89B +14.6% |
| Revenue (ttm) | 430.78M +21.0% |
| Net Income | -18.07M |
| EPS | -0.36 |
| Shares Out | 51.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 300,325 |
| Open | 36.64 |
| Previous Close | 36.75 |
| Day's Range | 36.05 - 36.78 |
| 52-Week Range | 27.56 - 40.72 |
| Beta | 0.74 |
| Analysts | Strong Buy |
| Price Target | 62.50 (+70.67%) |
| Earnings Date | Aug 6, 2026 |
About IMCR
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase ... [Read more]
Financial Performance
In 2025, Immunocore Holdings's revenue was $400.02 million, an increase of 28.95% compared to the previous year's $310.20 million. Losses were -$35.51 million, -30.48% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for IMCR stock is "Strong Buy." The 12-month stock price target is $62.5, which is an increase of 70.67% from the latest price.
News
Immunocore reinstated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye reinstated coverage of Immunocore (IMCR) with an Overweight rating and $50 price target The firm thinks Kimmtrak offers a “solid foundation” that is still growing in…
Immunocore price target raised to $43 from $40 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Immunocore (IMCR) to $43 from $40 and keeps an Equal Weight rating on the shares.
Immunocore Holdings Earnings Call Transcript: Q2 2026
Strong H1 2026 revenue growth was driven by KIMMTRAK's commercial momentum and high market penetration, with five-year survival data reinforcing its clinical value. Pipeline progress continues across melanoma, ovarian, lung, HIV, and autoimmune diseases, supported by a robust balance sheet.
Immunocore Holdings Earnings release: Q2 2026
Immunocore Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Immunocore Holdings Quarterly report: Q2 2026
Immunocore Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Immunocore Holdings Slides: Q2 2026
Immunocore Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Immunocore reports second quarter financial results and provides a business update
Immunocore reports second quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in ...
Immunocore Holdings Slides: Corporate presentation
Immunocore Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Immunocore price target raised to $35 from $34 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Immunocore (IMCR) to $35 from $34 and keeps a Neutral rating on the shares. The firm updated models in the…
Immunocore price target raised to $35 from $34 at Mizuho
Mizuho raised the firm’s price target on Immunocore (IMCR) to $35 from $34 and keeps an Underperform rating on the shares.
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 30 July 2026) Immunocore Holdings plc (Nasdaq: IMC...
Immunocore presents updated results from Phase 1/2 trial of brenetafusp
Immunocore (IMCR) announced updated results from its Phase 1/2 trial evaluating brenetafusp in patients with heavily pretreated advanced melanoma. The data is presented in a poster at the 2026 America...
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease con...
Immunocore Holdings Slides: Corporate presentation
Immunocore Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Immunocore reports first quarter financial results and provides a business update
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR:...
Immunocore Holdings Quarterly report: Q1 2026
Immunocore Holdings has published its Q1 2026 quarterly earnings report on May 6, 2026.
Immunocore Holdings Earnings release: Q1 2026
Immunocore Holdings released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Immunocore announces five-year overall survival data for Kimmtrak
Immunocore (IMCR) announced that Kimmtrak five-year overall survival, OS, was presented in an oral session at the American Association for Cancer Research, AACR, 2026 meeting. This is the longest, pro...
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Immunocore Holdings Proxy statement: Proxy filing
Immunocore Holdings filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Immunocore Holdings Transcript: 25th Annual Needham Virtual Healthcare Conference
The platform enables broad targeting of cancer and immune diseases, with KIMMTRAK driving strong revenue and global growth. Key upcoming milestones include pivotal data readouts in melanoma, HIV, and autoimmune programs, supported by a robust cash position and strategic flexibility.
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn.
Immunocore downgraded to Hold from Buy at Jefferies
Jefferies downgraded Immunocore (IMCR) to Hold from Buy with a price target of $33, down from $48, after assuming coverage of the name. While Immunocore has a real product in…
Immunocore Holdings Transcript: Leerink Global Healthcare Conference 2026
KIMMTRAK continues to drive strong commercial growth and is expanding into new indications, with pivotal data readouts expected in cutaneous melanoma, lung, and ovarian cancer in 2024. The pipeline also advances in HIV and autoimmune diseases, supported by a robust cash position and strategic investments.